ÂÜÀòÂÒÂ×

Dr. Niclas Stiernholm has decades of executive experience in the biotechnology industry, most recently as President and Chief Executive Officer of Trillium Therapeutics. Under his direction and leadership Trillium grew from one to 65 employees, raised over $200 million in the capital markets, and transitioned from a discovery-based academic spin-out venture to a clinical-stage immuno-oncology company, listed on both Nasdaq and the Toronto Stock Exchange. Dr. Stiernholm joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer when the company successfully completed its Initial Public Offering in 2002. In the past Dr. Stiernholm has served on numerous corporate, scientific and non-profit boards. He received his Ph.D. in immunology from the University of Toronto, where he also completed his postdoctoral training.